| Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320) |
|---|
| 09/19/2013 | US20130243761 Methods for prevention and treatment of inflammation using anti-chemokine antibodies |
| 09/19/2013 | US20130243760 Monoclonal antibodies against her2 antigens, and uses therefor |
| 09/19/2013 | US20130243759 Transgenic Animals |
| 09/19/2013 | US20130243756 Methods for Treating Diseases and HSV Using Antibodies to Aminophospholipids |
| 09/19/2013 | US20130243755 Novel human ulip/crmp protein and use thereof in diagnosis and treatment of cancers and paraneoplastic neurological syndromes |
| 09/19/2013 | US20130243752 Recombinantly produced antibody |
| 09/19/2013 | US20130243751 Glycoconjugates and their use as potential vaccines against infection by shigella flexneri |
| 09/19/2013 | US20130243750 Anti-ige antibodies and methods using same |
| 09/19/2013 | US20130243749 Humanized Monoclonal Antibodies and Methods of Use |
| 09/19/2013 | US20130243745 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-trna synthetases |
| 09/18/2013 | EP2639243A1 Anti single-strand type-iv collagen polypeptide antibody, and pharmaceutical, or agent for diagnosing, preventing or treating tumours, containing same |
| 09/18/2013 | EP2639242A2 Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| 09/18/2013 | EP2638916A1 Novel binding molecules with antitumoral activity |
| 09/18/2013 | EP2638403A2 Bin1 expression as a marker of skeletal muscle mass and neurological conditions |
| 09/18/2013 | EP2638394A1 Histone protein ubiquitination as a cancer biomarker |
| 09/18/2013 | EP2638155A1 Cells & vertebrates for enhanced somatic hypermutation and class switch recombination |
| 09/18/2013 | EP2638073A2 Protein complexes for antigen binding and methods of use |
| 09/18/2013 | EP2638072A2 Fusion proteins for hiv therapy |
| 09/18/2013 | EP2638071A1 Hydroxycholesterol immunoassay |
| 09/18/2013 | EP2638070A1 Methods and compositions for neural disease immunotherapy |
| 09/18/2013 | EP2638069A1 Human antibodies to human tnf-like ligand 1a (tl1a) |
| 09/18/2013 | EP2638068A1 Cxcr2 binding polypeptides |
| 09/18/2013 | EP2638067A2 Subcutaneously administered anti-il-6 receptor antibody |
| 09/18/2013 | EP2638066A2 Antibody scaffold for homogenous conjugation |
| 09/18/2013 | EP2638065A1 Actriia binding agents and uses thereof |
| 09/18/2013 | EP2638064A2 Cell culture medium and process for protein expression, said medium and process comprising a pam inhibitor |
| 09/18/2013 | EP2637693A2 System and method for generating micro-seismic events and characterizing properties of a medium with non-linear acoustic interactions |
| 09/18/2013 | EP2637692A2 Antibodies to tumor endothelial marker 8 |
| 09/18/2013 | EP2637691A2 Materials and methods for directing an immune response to an epitope |
| 09/18/2013 | EP2637670A1 Prevention of adverse effects caused by cd3 specific binding domains |
| 09/18/2013 | CN1630665B Anti-A beta antibodies and their use |
| 09/18/2013 | CN103314011A Human antibodies to the glucagon receptor |
| 09/18/2013 | CN103313728A CD89 activation in therapy |
| 09/18/2013 | CN103313726A Identification and enrichment of cell subpopulations |
| 09/18/2013 | CN103305473A Bluetongue virus serum 1 (BTV1) VP2 protein monoclonal antibody (BTV1-4B6), B-cell epitope polypeptide identified by BTV1-4B6 and application of BTV1-4B6 |
| 09/18/2013 | CN103305472A Bluetongue virus serum 1 (BTV1) VP2 protein monoclonal antibody (BTV1-3E8), B-cell epitope polypeptide identified by BTV1-3E8 and application of BTV1-3E8 |
| 09/18/2013 | CN103305471A Monoclonal antibody BTV8-VP2-4D9 resist ant to bluetongue virus serum 8 type VP2 protein, B-cell epitope peptide identified thereby and application |
| 09/18/2013 | CN103305470A Monoclonal antibody BTV8-VP2-3E11 resistant to bluetongue virus serum 8 type VP2 protein, B-cell epitope peptide identified thereby and application |
| 09/18/2013 | CN103304667A Humanized anti-beta7 antagonists and uses therefor |
| 09/18/2013 | CN103304666A Procalcitonin monoclonal antibody and application thereof |
| 09/18/2013 | CN103304665A NT-proBNP (Amino terminal pro-brain natriuretic peptide precursor) resistant monoclonal antibody and application thereof |
| 09/18/2013 | CN103304664A Method for preparing pathogenic aeromonas veronii egg yolk antibody |
| 09/18/2013 | CN103304663A Single-chain antibody of chicken Newcastle disease virus P protein, preparation method and use of single-chain antibody |
| 09/18/2013 | CN103304662A Monoclonal antibody of leucomalachite green and preparation method and usage thereof |
| 09/18/2013 | CN103304658A Radiosensitive polypeptide mark SPG01 for nasopharynx cancer and ELISA (Enzyme-Linked Immuno Sorbent Assay) kit thereof |
| 09/18/2013 | CN103304495A Preparation method and applications of olaquindox metabolite hapten |
| 09/18/2013 | CN102675463B Carbendazim monoclonal antibody, preparation method and application thereof |
| 09/18/2013 | CN102659942B Vibrio parahaemolyticus flagellin monoclonal antibody and antigen capture ELISA (enzyme-linked immunosorbent assay) kit |
| 09/18/2013 | CN102358751B Human fibrinogen-like protein 2 prothrombinase immunogenicity peptide and use thereof |
| 09/18/2013 | CN102245767B Immunoassay method for human CXCL1 protein |
| 09/18/2013 | CN102206253B Actin depolymerizing factor epitope, actin depolymerizing factor antibody and use thereof |
| 09/18/2013 | CN102167746B SPG-(Streptococcal Protein G) antibody polymer and preparation method as well as application thereof |
| 09/18/2013 | CN102127150B Nestin portion polypeptide and application thereof |
| 09/18/2013 | CN101948540B Preparation of novel anti-EGFR human source antibody MIL27 and application thereof |
| 09/18/2013 | CN101675076B Engineered anti-il-23r antibodies |
| 09/18/2013 | CN101416061B Method for the detection and/or enrichment of analyte proteins and/or analyte peptides from a complex protein mixture |
| 09/18/2013 | CN101300272B Compositions and methods for treating proliferative disorders |
| 09/18/2013 | CN101282994B Anti-CD26 antibodies and methods of use thereof |
| 09/17/2013 | US8536313 Monoclonal antibody having neutralizing activity against MMP13 |
| 09/17/2013 | US8536312 Monoclonal antibodies with specificity for fetal erythroid cells |
| 09/17/2013 | US8536311 Inhibitor protein of the wnt signal pathway |
| 09/17/2013 | US8536309 Methods of producing anti-IL-22RA antibodies |
| 09/17/2013 | US8536308 Antibodies to interleukin-6 |
| 09/17/2013 | US8536303 Polypeptide inhibitors of HSP27 kinase and uses therefor |
| 09/17/2013 | US8536122 Acylated GLP-1 compounds |
| 09/17/2013 | US8536118 Methods and compositions for modulating hyperstabilized c-met |
| 09/17/2013 | US8535912 Chimeric fibroblast growth factors with altered receptor specificity |
| 09/17/2013 | US8535899 Assay for identifying a modulator of HIF hydroxylase |
| 09/17/2013 | US8535890 Methods to determine immunogenicity of humanized anti-tag 72 CC49 antibodies |
| 09/17/2013 | US8535690 Tumor specific animal proteins |
| 09/17/2013 | US8535688 Vaccine |
| 09/17/2013 | US8535681 Sustained drug delivery system |
| 09/17/2013 | US8535678 Anti-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
| 09/17/2013 | US8535676 Antibody therapy |
| 09/17/2013 | US8535673 A humanized antibody that specifically binds an epitope contained within positions 13-28 of A beta; used for treating Alzheimer's disease in both asymptomatic patients and those currently showing symptoms of disease. |
| 09/17/2013 | US8535672 Superantigen binding site wherein T-cell costimulatory pathway is one of CD28/B7 T cell costimulatory pathway, CD40 ligand/CD40, CD2/CD58 and LFA-1 (CD18)/ICAM-1 (CD54) costimulatory pathway; toxic shock syndrome caused by a pyrogenic exotoxin; anticarcinogenic and antiproliferative agents |
| 09/17/2013 | US8535671 Methods of reducing CRP and/or increasing serum albumin in patients in need using IL-6 antibodies of defined epitopic specificity |
| 09/17/2013 | US8535668 Chimeric anti-ricin antibody |
| 09/17/2013 | US8535667 Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers |
| 09/17/2013 | US8535666 Antibody (11C7) anti Nogo-A and its pharmaceutical use |
| 09/17/2013 | US8535664 Method of treating a pathological syndrome and a pharmaceutical agent |
| 09/17/2013 | CA2606081C Combination of the application of antibodies for immunostimulation together with glucocorticoids |
| 09/17/2013 | CA2563887C Mite allergen zen 1 |
| 09/17/2013 | CA2562711C Cab molecules |
| 09/17/2013 | CA2555666C Therapeutic and diagnostic conjugates for use with multispecific antibodies |
| 09/17/2013 | CA2532394C Rg1 antibodies and uses thereof |
| 09/17/2013 | CA2402380C Leafy cotyledon2 genes and their uses |
| 09/12/2013 | WO2013134743A1 Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof |
| 09/12/2013 | WO2013134516A1 Methods of treatment with angiopoietin-2 antibodies |
| 09/12/2013 | WO2013134414A1 Bispecific antibodies with an fgf2 binding domain |
| 09/12/2013 | WO2013134365A1 TGF-β1 SPECIFIC ANTIBODIES AND METHODS AND USES THEREOF |
| 09/12/2013 | WO2013134263A1 Common light chain mouse |
| 09/12/2013 | WO2013134138A1 Engineered antibody-interferon mutant fusion molecules |
| 09/12/2013 | WO2013134052A1 Il-17 antibody formulation |
| 09/12/2013 | WO2013133917A1 Sandwich assay for immunosuppressant drugs |
| 09/12/2013 | WO2013133258A1 Antibody purification method, and carrier for use in purification of antibody |
| 09/12/2013 | WO2013133253A1 Anticancer agent |
| 09/12/2013 | WO2013132495A1 Compositions for inhibition of quiescin sulfhydryl oxidase (qsox1) and uses of same |
| 09/12/2013 | WO2013132268A1 Chemical modification of antibodies |
| 09/12/2013 | WO2013132063A1 Treatment of mucositis with immunoglobulin |